Creative Medical Technology Share Price Today

Creative Medical reports 93% response rate in knee osteoarthritis study

93% of patients (28 of 30) met clinical improvement criteria in the six-month pilot study. Average pain scores declined by approximately 65% from baseline to six months. WOMAC scores for pain, stiffness, and physical limitations improved by 52%. No serious adverse events were reported during the follow-up period. Study was open-label and single-arm, limiting isolation of placebo effects.

Creative Medical acquires 4M BioDefense shares, stake hits 80%

Creative Medical acquired 4 million BioDefense shares on September 24, 2026. Purchase price included $200,000 cash and 1 million Creative Medical shares. Total ownership in BioDefense increased to 80% of outstanding shares. Timothy Warbington is CEO of both companies and owns all of CAC.

Creative Medical files US patent for Ultrasome platform

Creative Medical files new US provisional patent for Ultrasome platform. Application expands IP protection for cell-free regenerative medicine. Covers product composition, potency, and manufacturing methods. Includes stability characteristics and therapeutic applications.

Creative Medical completes ADAPT trial enrollment, eyes Phase 3 planning

Creative Medical Technology Holdings completed enrollment and treatment for its ADAPT trial evaluating Olastrocel for chronic lower back pain. Interim data showed significant improvements in functional disability and pain reduction with no serious adverse events. The company expects reduced clinical costs to extend its operating runway as it prepares for RMAT evaluation and Phase 3 planning.

Creative Medical secures US patent for exosome-based diabetes therapy

Creative Medical Technology Holdings secured a USPTO Notice of Allowance for a patent on exosome-based immunotherapy for Type 1 diabetes. This strengthens IP for its MyeloCelz platform and complements clinical programs CELZ-101 and CELZ-201. The company’s IP estate now includes ~60 patents/applications, targeting an $18 billion global T1D market.

Creative Medical Technology Holdings advances regenerative medicine programs

Creative Medical Technology Holdings, Inc. provided a mid-year update highlighting advancements in its regenerative medicine and biodefense programs. The company reported positive interim data for Olastrocel (CELZ-201) in chronic lower back pain and breakthrough pilot results for Ultrasome in osteoarthritis. Its CELZ-Biodefense platform advanced into a nationwide data collection phase targeting 1,000 veterans.